163 related articles for article (PubMed ID: 23178555)
1. Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients.
Pan CQ; Hu KQ; Tsai N
Antivir Ther; 2013; 18(7):841-52. PubMed ID: 23178555
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of entecavir and/or tenofovir in hepatitis B compensated and decompensated cirrhotic patients in clinical practice.
Miquel M; Núñez Ó; Trapero-Marugán M; Díaz-Sánchez A; Jiménez M; Arenas J; Canós AP
Ann Hepatol; 2013; 12(2):205-12. PubMed ID: 23396731
[TBL] [Abstract][Full Text] [Related]
3. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
4. Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
Papatheodoridis GV; Dalekos GN; Yurdaydin C; Buti M; Goulis J; Arends P; Sypsa V; Manolakopoulos S; Mangia G; Gatselis N; Keskın O; Savvidou S; Hansen BE; Papaioannou C; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HL; Lampertico P
J Hepatol; 2015 Feb; 62(2):363-70. PubMed ID: 25195548
[TBL] [Abstract][Full Text] [Related]
5. Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma.
Pellicelli AM; Vignally P; Messina V; Izzi A; Mazzoni E; Barlattani A; Bacca D; Romano M; Mecenate F; Stroffolini T; Furlan C; Picardi A; Gentilucci UV; Gulminetti R; Bonaventura ME; Villani R; D'Ambrosio C; Paffetti A; Mastropietro C; Marignani M; Fondacaro L; Cerasari G; Andreoli A; Barbarini G
Ann Hepatol; 2014; 13(4):376-85. PubMed ID: 24927608
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir.
Ridruejo E
World J Gastroenterol; 2014 Jun; 20(23):7169-80. PubMed ID: 24966587
[TBL] [Abstract][Full Text] [Related]
7. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population.
Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of treatment with nucleoside and nucleotide analogues (entecavir and tenofovir) for chronic hepatitis B.
Asselah T; Marcellin P
Clin Liver Dis; 2013 Aug; 17(3):445-50. PubMed ID: 23905815
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey.
Güzelbulut F; Gökçen P; Can G; Adalı G; Değirmenci Saltürk AG; Aslan E; Özdil K; Doğanay HL
Turk J Gastroenterol; 2021 Apr; 32(4):412-421. PubMed ID: 34231488
[TBL] [Abstract][Full Text] [Related]
10. A multicenter study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in South Korea.
Kim SU; Seo YS; Lee HA; Kim MN; Lee YR; Lee HW; Park JY; Kim DY; Ahn SH; Han KH; Hwang SG; Rim KS; Um SH; Tak WY; Kweon YO; Kim BK; Park SY
J Hepatol; 2019 Sep; 71(3):456-464. PubMed ID: 30959156
[TBL] [Abstract][Full Text] [Related]
11. Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV; Dalekos GN; Idilman R; Sypsa V; Van Boemmel F; Buti M; Calleja JL; Goulis J; Manolakopoulos S; Loglio A; Papatheodoridi M; Gatselis N; Veelken R; Lopez-Gomez M; Hansen BE; Savvidou S; Kourikou A; Vlachogiannakos J; Galanis K; Yurdaydin C; Esteban R; Janssen HLA; Berg T; Lampertico P
J Hepatol; 2020 Nov; 73(5):1037-1045. PubMed ID: 32553667
[TBL] [Abstract][Full Text] [Related]
12. Emerging pipeline drugs for hepatitis B infection.
Cox N; Tillmann H
Expert Opin Emerg Drugs; 2011 Dec; 16(4):713-29. PubMed ID: 22195605
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naïve patients with chronic hepatitis B.
Lok AS; Trinh H; Carosi G; Akarca US; Gadano A; Habersetzer F; Sievert W; Wong D; Lovegren M; Cohen D; Llamoso C
Gastroenterology; 2012 Sep; 143(3):619-628.e1. PubMed ID: 22643350
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate for the treatment of hepatitis B infection.
Adusumilli S
Drugs Today (Barc); 2009 Sep; 45(9):679-85. PubMed ID: 19956809
[TBL] [Abstract][Full Text] [Related]
15. First-line monotherapies of tenofovir and entecavir have comparable efficacies in hepatitis B treatment.
Ozaras R; Mete B; Ceylan B; Ozgunes N; Gunduz A; Karaosmanoglu H; Cagatay A; Gokturk K; Erdem L; Kocak F; Senates E; Tabak F
Eur J Gastroenterol Hepatol; 2014 Jul; 26(7):774-80. PubMed ID: 24901822
[TBL] [Abstract][Full Text] [Related]
16. Managing hepatitis B to prevent liver cancer: recent advances.
Strasser SI
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):409-15. PubMed ID: 24580046
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis.
Köklü S; Tuna Y; Gülşen MT; Demir M; Köksal AŞ; Koçkar MC; Aygün C; Coban S; Ozdil K; Ataseven H; Akin E; Pürnak T; Yüksel I; Ataseven H; Ibiş M; Yildirim B; Nadir I; Küçükazman M; Akbal E; Yüksel O; Başar O; Alkan E; Baykal O
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):88-94. PubMed ID: 23063679
[TBL] [Abstract][Full Text] [Related]
18. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review.
Tseng CH; Tseng CM; Wu JL; Hsu YC; El-Serag HB
J Gastroenterol Hepatol; 2020 Oct; 35(10):1684-1693. PubMed ID: 32343431
[TBL] [Abstract][Full Text] [Related]
19. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis.
Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK
Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587
[TBL] [Abstract][Full Text] [Related]
20. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
Hadziyannis SJ
Expert Opin Investig Drugs; 2007 Jun; 16(6):777-86. PubMed ID: 17501691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
